Human Coagulation Factor VIII Consumption Market Report 2018-2023

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Human Coagulation Factor VIII market for 2018-2023.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/global-human-coagulation-factor-viii-2018-2023-550

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.

The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.

Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.

Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.

Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.

Over the next five years, LPI(LP Information) projects that Human Coagulation Factor VIII will register a 2.8% CAGR in terms of revenue, reach US$ 8770 million by 2023, from US$ 7440 million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Coagulation Factor VIII market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

  • Recombinant Factor VIII
  • Plasma-derived Factor VIII

Segmentation by application:

  • Hemophilia A
  • Spontanous / Trauma
  • Surgical
  • Other

This report also splits the market by region:

  • Americas
  • United States
  • Canada
  • Mexico
  • Brazil
  • APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Spain
  • Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

  • Shire (Baxter)
  • Bayer
  • CSL
  • Pfizer
  • Grifols
  • Biogen
  • Octapharma
  • NovoNordisk
  • Greencross
  • Kedrion
  • BPL
  • Hualan Bio
  • RAAS

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

  • To study and analyze the global Human Coagulation Factor VIII consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
  • To understand the structure of Human Coagulation Factor VIII market by identifying its various subsegments.
  • Focuses on the key global Human Coagulation Factor VIII manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
  • To analyze the Human Coagulation Factor VIII with respect to individual growth trends, future prospects, and their contribution to the total market.
  • To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
  • To project the consumption of Human Coagulation Factor VIII submarkets, with respect to key regions (along with their respective key countries).
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Table of content

2018-2023 Global Human Coagulation Factor VIII Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Coagulation Factor VIII Consumption 2013-2023
2.1.2 Human Coagulation Factor VIII Consumption CAGR by Region
2.2 Human Coagulation Factor VIII Segment by Type
2.2.1 Recombinant Factor VIII
2.2.2 Plasma-derived Factor VIII
2.3 Human Coagulation Factor VIII Consumption by Type
2.3.1 Global Human Coagulation Factor VIII Consumption Market Share by Type (2013-2018)
2.3.2 Global Human Coagulation Factor VIII Revenue and Market Share by Type (2013-2018)
2.3.3 Global Human Coagulation Factor VIII Sale Price by Type (2013-2018)
2.4 Human Coagulation Factor VIII Segment by Application
2.4.1 Hemophilia A
2.4.2 Spontanous / Trauma
2.4.3 Surgical
2.4.4 Other
2.5 Human Coagulation Factor VIII Consumption by Application
2.5.1 Global Human Coagulation Factor VIII Consumption Market Share by Application (2013-2018)
2.5.2 Global Human Coagulation Factor VIII Value and Market Share by Application (2013-2018)
2.5.3 Global Human Coagulation Factor VIII Sale Price by Application (2013-2018)

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports